New Study: Lipid Nanoparticles in COVID Vaccines Travel to Vital Organs
Groundbreaking Findings – Lipid Nanoparticles Travel to Vital Organs, Including Heart
A groundbreaking study published in Nature Biotechnology has revealed that lipid nanoparticles (LNPs) used in COVID-19 mRNA vaccines do not remain at the injection site but instead travel throughout the body, reaching vital organs such as the heart, liver, kidneys, and spleen. The findings challenge prior claims by public health officials that LNPs remain localized.
Key Findings
- Researchers developed a new technology, Single Cell Precision Nanocarrier Identification, to track the distribution of nanocarriers like LNPs after injection.
- Even at low doses, LNPs carrying SARS-CoV-2 spike protein mRNA were found in multiple organs.
- The study found changes in heart tissue that align with myocarditis and pericarditis cases reported post-vaccination.
- Pfizer’s own research had previously indicated that LNPs disperse rapidly, yet early public health messaging claimed they stayed in muscle tissue.
Potential Implications
- The widespread biodistribution of LNPs raises concerns about their long-term effects, particularly regarding cardiac complications.
- Experts argue that such biodistribution studies should have been conducted before mass vaccination rather than afterward.
- With over 27,000 cases of myocarditis and pericarditis reported in the U.S. to VAERS, researchers call for further investigation into the safety of LNP-based vaccines.
- Critics demand that gene therapy-like injections be reevaluated and possibly removed from the market.
Limitations and Future Research
While this study offers critical insights, its method cannot yet be applied to living human subjects. Further research is needed to determine the full extent of these findings in humans and whether regulatory bodies should reconsider LNP-based vaccine approvals.
This new evidence underscores the need for transparency and rigorous testing in vaccine development to ensure public safety.
Source: CHD, The Defender
Intramuscular mRNA Injections Distribute to Vital Organs, Resulting in Systemic Spike Protein Production – Nicolas Hulscher, MPH